Recommendation of the President – Brukinsa (zanubrutinib)
On 6 February 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 20/2026 on the reimbursement of the medicinal product Brukinsa (zanubrutinib) under drug program B.79 “Treatment of patients with chronic lymphocytic leukemia or small B-cell lymphoma (ICD-10: C91.1)”